Generic Name: duvelisib
Drug Class: Targeted Therapy Medications
Approval Status: Approved
Generic Version Available: No
Copiktra is a PI3K kinase inhibitor approved for relapsed or refractory chronic lymphocytic leukemia, small lymphocytic lymphoma and follicular lymphoma.
Copiktra inhibits phosphatidylinositol-3-kinase (PI3K), an enzyme that is part of signaling pathways that play a role in cell growth and metabolism. It is active against forms of PI3K that are present on cancerous B cells, which grow out of control in people with leukemia and lymphoma.
The DUO clinical trial showed that Copiktra slows disease progression in people with chronic lymphocytic leukemia or small lymphocytic lymphoma. Copiktra received accelerated approval for follicular lymphoma based on promising response rates in the DYNAMO study.
Copiktra is taken as a pill twice daily.
Common side effects include diarrhea, skin rash, fatigue, fever and pain. Copiktra can cause depletion of white blood cells (neutropenia), which can lead to infections. Potentially serious side effects include bowel inflammation (colitis), lung inflammation (pneumonitis) and severe skin reactions.
For More Info: https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm621503.htm
Co-Pay Program Info: https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm621503.htm
Patient Assistance Program Info: https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm621503.htm
Last Reviewed: September 24, 2018